BIM 株式概要
bioMérieux S.A.は、アメリカ大陸、ヨーロッパ、中東、アフリカ、アジア太平洋地域で、感染症診断のための体外診断用医薬品の開発と販売を行っています。 詳細
報酬
リスク分析
リスクチェックの結果、BIM 、リスクは検出されなかった。
bioMérieux S.A. 競合他社
価格と性能
過去の株価 | |
---|---|
現在の株価 | €96.50 |
52週高値 | €111.50 |
52週安値 | €88.25 |
ベータ | 0.22 |
11ヶ月の変化 | -7.74% |
3ヶ月変化 | -6.67% |
1年変化 | -1.77% |
33年間の変化 | -22.46% |
5年間の変化 | 17.61% |
IPOからの変化 | 865.00% |
最新ニュース
Is bioMérieux (EPA:BIM) Using Too Much Debt?
Nov 01Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?
Oct 14bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing
Sep 26bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Sep 08Return Trends At bioMérieux (EPA:BIM) Aren't Appealing
Aug 03Recent updates
Is bioMérieux (EPA:BIM) Using Too Much Debt?
Nov 01Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?
Oct 14bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing
Sep 26bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Sep 08Return Trends At bioMérieux (EPA:BIM) Aren't Appealing
Aug 03bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
May 30Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)
Apr 18bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Mar 31bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 17These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Mar 15bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
Jan 27bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward
Jan 06A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 16These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Oct 23bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger
Oct 05There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings
Sep 15Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Jun 30Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down
Jun 09Is bioMérieux (EPA:BIM) Using Too Much Debt?
Mar 31The Return Trends At bioMérieux (EPA:BIM) Look Promising
Feb 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jan 27bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet
Dec 16bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth
Oct 18Is bioMérieux (EPA:BIM) Using Too Much Debt?
Sep 14Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital
Aug 11An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued
Jul 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jul 05bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
May 26Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns
May 11bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year
Apr 23bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85
Apr 09bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
Mar 25Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Mar 13I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease
Feb 08Why We Like The Returns At bioMérieux (EPA:BIM)
Dec 21Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 07Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching
Nov 07Is bioMérieux (EPA:BIM) A Risky Investment?
Oct 07Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital
Sep 22Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Aug 06There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital
Jun 15A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)
May 31Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Apr 30bioMérieux (EPA:BIM) Could Easily Take On More Debt
Mar 28The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested
Mar 13Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Feb 25If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns
Feb 09If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late
Jan 20Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?
Dec 30These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Dec 17株主還元
BIM | FR Medical Equipment | FR 市場 | |
---|---|---|---|
7D | -2.5% | 2.7% | -0.3% |
1Y | -1.8% | 26.7% | -3.5% |
業界別リターン: BIM過去 1 年間で26.7 % の収益を上げたFrench Medical Equipment業界を下回りました。
リターン対市場: BIM過去 1 年間で-3.5 % の収益を上げたFrench市場を上回りました。
価格変動
BIM volatility | |
---|---|
BIM Average Weekly Movement | 3.4% |
Medical Equipment Industry Average Movement | 5.4% |
Market Average Movement | 4.5% |
10% most volatile stocks in FR Market | 9.2% |
10% least volatile stocks in FR Market | 2.2% |
安定した株価: BIM過去 3 か月間に大きな価格変動はありませんでした。
時間の経過による変動: BIMの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。
会社概要
設立 | 従業員 | CEO(最高経営責任者 | ウェブサイト |
---|---|---|---|
1963 | 13,696 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A.は、アメリカ、ヨーロッパ、中東、アフリカ、アジア太平洋地域で、感染症診断のための体外診断ソリューションを開発・販売しています。同社は、発色剤培地CHROMID RANGE、カルバペネマーゼ産生菌検出用生化学検査RAPIDEC CARBA NP、大気・地表水モニタリングシステム、血液サンプル培養システムBACT/ALERT VIRTUO BACT/ALERT 3D、マルチプレックスポリメラーゼ連鎖反応(PCR)システムBIOFIRE、ポイントオブケアシステムBIOFIRE SPOTFIRE Lowplex PCR、質量分析システムVITEK MSを提供しています;VITEK 2、自動同定・抗菌薬感受性試験(AST)システム、API RANGE標準化IDストリップ、VITEK REVEAL Rapid ASTシステム、培地上のETEST Gradient法、疫学的モニタリング用BIOMERIEUX EPISEQ CS全ゲノムシーケンシングソリューション、VIDASB-R-A-H-M-S PCTTM、重症細菌感染症/敗血症の特異的マーカー。また、診断と臨床的意思決定をサポートする実用的な情報を提供するソフトウェアBiomérieux vision suite、培地と関連機器、ARGENE Monoplex PCRテスト、分子生物学研究室の自動化と抽出のための製品NUCLISENSレンジ、DNAとRNA抽出のためのEMAGシステム、PCRテストを処理するためのサンプルの自動調製ステーションESTREAM、食品産業用の微生物の検出のためのGENE-UPとVERIFLOWレンジを提供しています。bioMérieux S.A.は以前はB-D Mérieuxとして知られていた。bioMérieux S.A.はInstitut Mérieux S.A.の子会社である。
bioMérieux S.A. 基礎のまとめ
BIM 基礎統計学 | |
---|---|
時価総額 | €11.51b |
収益(TTM) | €411.30m |
売上高(TTM) | €3.81b |
27.7x
PER(株価収益率3.0x
P/SレシオBIM は割高か?
公正価値と評価分析を参照収益と収入
BIM 損益計算書(TTM) | |
---|---|
収益 | €3.81b |
売上原価 | €1.69b |
売上総利益 | €2.12b |
その他の費用 | €1.71b |
収益 | €411.30m |
直近の収益報告
Jun 30, 2024
次回決算日
該当なし
一株当たり利益(EPS) | 3.49 |
グロス・マージン | 55.72% |
純利益率 | 10.81% |
有利子負債/自己資本比率 | 10.1% |
BIM の長期的なパフォーマンスは?
過去の実績と比較を見る